华蟾素注射液联合全身化疗治疗中晚期乳腺癌的临床效果(1)
[摘要]目的 探讨中晚期乳腺癌患者应用华蟾素注射液联合全身化疗的效果。方法 选取2016年1月～2018年1月本院收治的112例中晚期女性乳腺癌患者作为研究对象，随机分为试验组(56例)和对照组(56例)。对照组采用化疗方案，试验组采用华蟾素注射液联合全身化疗方案。比较两组的临床疗效、生活质量变化情况以及不良反应发生率。结果 治疗后，试验组的总有效率为73.21%(41/56)，明显高于对照组的53.57%(30/56)，差异有统计学意义(χ2=4.655，P=0.031);试验组的生活质量明显优于对照组，差异有统计学意义(P<0.05)。治疗后，试验组的急性皮疹、胃肠道反应发生率明显低于对照组(χ2=11.720、6.619，P=0.001、0.010)。结论 对于中晚期乳腺癌患者，华蟾素注射液联合全身化疗的临床疗效显著，可明显改善其生活质量，且不良反应少。
[关键词]华蟾素注射液;全身化疗;中晚期乳腺癌;临床疗效
[中图分类号] R737.9 [文献标识码] A [文章编号] 1674-4721(2019)7(b)-0043-03
[Abstract] Objective To investigate the effect of Cinobufotalin Injection combined with systemic chemotherapy in patients with advanced breast cancer. Methods A total of 112 women with advanced breast cancer admitted to our hospital from January 2016 to January 2018 were selected and randomly divided into the experimental group (56 cases) and the control group (56 cases). The control group was treated with chemotherapy， while the experimental group was treated with Cinobufotalin Injection combined with systemic chemotherapy. The clinical efficacy， quality of life and the incidence of adverse reactions were compared between the two groups. Results After treatment， the total effective rate of the experimental group was 73.21% (41/56)， which was significantly higher than 53.57% of the control group (30/56)， with statistical significance (χ2=4.655， P=0.031). The quality of life of the experimental group was significantly better than that of the control group， and the difference was statistically significant (P<0.05). After treatment， the incidence of acute rash and gastrointestinal reaction in the experimental group was significantly lower than that in the control group (χ2=11.720， 6.619; P=0.001， 0.010). Conclusion For patients with advanced breast cancer， Cinobufotalin Injection combined with systemic chemotherapy has significant clinical efficacy， which can significantly improve their quality of life， and less adverse reactions.
[Key words] Cinobufotalin Injection; Systemic chemotherapy; Advanced breast cancer; Clinical efficacy
乳腺癌是發生在乳腺腺上皮组织的恶性肿瘤，近年来，其发病率呈逐渐上升的趋势。目前，乳腺癌对女性身心健康造成极大的影响，已成为当前社会的重大公共卫生问题[1]。原位乳腺癌并不致命，但由于乳腺癌细胞之间连接松散，容易脱落，使游离的癌细胞随血液或淋巴液播散全身，发生转移，导致病情恶化[2]。乳腺癌不易诊治，早期发现、早期诊断是提高疗效的关键。化疗虽然可有效杀死乳腺癌细胞，但亦存在胃肠道反应、骨髓抑制等毒副作用，使患者难以耐受。相关研究显示[3]，华蟾素注射液具有解毒、消肿、镇痛的功效，可用于中、晚期肿瘤，明显提高患者的生活质量，且不良反应较小。本研究旨在探讨中晚期乳腺癌患者应用华蟾素注射液联合全身化疗的临床疗效，现报道如下。
1资料与方法
1.1一般资料
选取2016年1月～2018年1月本院收治的112例中晚期女性乳腺癌患者作为研究对象，年龄33～66岁，平均(42.67±3.12)岁。随机将112例患者分为试验组(56例)和对照组(56例)。试验组中，年龄33～66岁，平均(41.85±2.25)岁;对照组中，年龄35～66岁，平均(43.56±3.02)岁。两组患者的年龄等一般资料比较，差异无统计学意义(P>0.05)，具有可比性。此外，本研究符合相关医学伦理学标准。, 百拇医药(孙成 刘艳翠 赵微)
[关键词]华蟾素注射液;全身化疗;中晚期乳腺癌;临床疗效
[中图分类号] R737.9 [文献标识码] A [文章编号] 1674-4721(2019)7(b)-0043-03
[Abstract] Objective To investigate the effect of Cinobufotalin Injection combined with systemic chemotherapy in patients with advanced breast cancer. Methods A total of 112 women with advanced breast cancer admitted to our hospital from January 2016 to January 2018 were selected and randomly divided into the experimental group (56 cases) and the control group (56 cases). The control group was treated with chemotherapy， while the experimental group was treated with Cinobufotalin Injection combined with systemic chemotherapy. The clinical efficacy， quality of life and the incidence of adverse reactions were compared between the two groups. Results After treatment， the total effective rate of the experimental group was 73.21% (41/56)， which was significantly higher than 53.57% of the control group (30/56)， with statistical significance (χ2=4.655， P=0.031). The quality of life of the experimental group was significantly better than that of the control group， and the difference was statistically significant (P<0.05). After treatment， the incidence of acute rash and gastrointestinal reaction in the experimental group was significantly lower than that in the control group (χ2=11.720， 6.619; P=0.001， 0.010). Conclusion For patients with advanced breast cancer， Cinobufotalin Injection combined with systemic chemotherapy has significant clinical efficacy， which can significantly improve their quality of life， and less adverse reactions.
[Key words] Cinobufotalin Injection; Systemic chemotherapy; Advanced breast cancer; Clinical efficacy
乳腺癌是發生在乳腺腺上皮组织的恶性肿瘤，近年来，其发病率呈逐渐上升的趋势。目前，乳腺癌对女性身心健康造成极大的影响，已成为当前社会的重大公共卫生问题[1]。原位乳腺癌并不致命，但由于乳腺癌细胞之间连接松散，容易脱落，使游离的癌细胞随血液或淋巴液播散全身，发生转移，导致病情恶化[2]。乳腺癌不易诊治，早期发现、早期诊断是提高疗效的关键。化疗虽然可有效杀死乳腺癌细胞，但亦存在胃肠道反应、骨髓抑制等毒副作用，使患者难以耐受。相关研究显示[3]，华蟾素注射液具有解毒、消肿、镇痛的功效，可用于中、晚期肿瘤，明显提高患者的生活质量，且不良反应较小。本研究旨在探讨中晚期乳腺癌患者应用华蟾素注射液联合全身化疗的临床疗效，现报道如下。
1资料与方法
1.1一般资料
选取2016年1月～2018年1月本院收治的112例中晚期女性乳腺癌患者作为研究对象，年龄33～66岁，平均(42.67±3.12)岁。随机将112例患者分为试验组(56例)和对照组(56例)。试验组中，年龄33～66岁，平均(41.85±2.25)岁;对照组中，年龄35～66岁，平均(43.56±3.02)岁。两组患者的年龄等一般资料比较，差异无统计学意义(P>0.05)，具有可比性。此外，本研究符合相关医学伦理学标准。, 百拇医药(孙成 刘艳翠 赵微)